ATXI Avenue Therapeutics, Inc.Stock Price & Overview
$0.210.04 (+21.56%)4:00 PM 11/30/23
NASDAQ | $USD | Pre-Market: $0.18 -0.03 (-12.97%) 8:00 AM
People Also Follow
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.